Cargando…

Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications

Several flavonoids have been recognized as nutraceuticals, and myricetin is a good example. Myricetin is commonly found in plants and their antimicrobial and antioxidant activities is well demonstrated. One of its beneficial biological effects is the neuroprotective activity, showing preclinical act...

Descripción completa

Detalles Bibliográficos
Autores principales: Taheri, Yasaman, Suleria, Hafiz Ansar Rasul, Martins, Natália, Sytar, Oksana, Beyatli, Ahmet, Yeskaliyeva, Balakyz, Seitimova, Gulnaz, Salehi, Bahare, Semwal, Prabhakar, Painuli, Sakshi, Kumar, Anuj, Azzini, Elena, Martorell, Miquel, Setzer, William N., Maroyi, Alfred, Sharifi-Rad, Javad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395214/
https://www.ncbi.nlm.nih.gov/pubmed/32738903
http://dx.doi.org/10.1186/s12906-020-03033-z
_version_ 1783565367058104320
author Taheri, Yasaman
Suleria, Hafiz Ansar Rasul
Martins, Natália
Sytar, Oksana
Beyatli, Ahmet
Yeskaliyeva, Balakyz
Seitimova, Gulnaz
Salehi, Bahare
Semwal, Prabhakar
Painuli, Sakshi
Kumar, Anuj
Azzini, Elena
Martorell, Miquel
Setzer, William N.
Maroyi, Alfred
Sharifi-Rad, Javad
author_facet Taheri, Yasaman
Suleria, Hafiz Ansar Rasul
Martins, Natália
Sytar, Oksana
Beyatli, Ahmet
Yeskaliyeva, Balakyz
Seitimova, Gulnaz
Salehi, Bahare
Semwal, Prabhakar
Painuli, Sakshi
Kumar, Anuj
Azzini, Elena
Martorell, Miquel
Setzer, William N.
Maroyi, Alfred
Sharifi-Rad, Javad
author_sort Taheri, Yasaman
collection PubMed
description Several flavonoids have been recognized as nutraceuticals, and myricetin is a good example. Myricetin is commonly found in plants and their antimicrobial and antioxidant activities is well demonstrated. One of its beneficial biological effects is the neuroprotective activity, showing preclinical activities on Alzheimer, Parkinson, and Huntington diseases, and even in amyotrophic lateral sclerosis. Also, myricetin has revealed other biological activities, among them as antidiabetic, anticancer, immunomodulatory, cardiovascular, analgesic and antihypertensive. However, few clinical trials have been performed using myricetin as nutraceutical. Thus, this review provides new insights on myricetin preclinical pharmacological activities, and role in selected clinical trials.
format Online
Article
Text
id pubmed-7395214
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73952142020-08-03 Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications Taheri, Yasaman Suleria, Hafiz Ansar Rasul Martins, Natália Sytar, Oksana Beyatli, Ahmet Yeskaliyeva, Balakyz Seitimova, Gulnaz Salehi, Bahare Semwal, Prabhakar Painuli, Sakshi Kumar, Anuj Azzini, Elena Martorell, Miquel Setzer, William N. Maroyi, Alfred Sharifi-Rad, Javad BMC Complement Med Ther Review Several flavonoids have been recognized as nutraceuticals, and myricetin is a good example. Myricetin is commonly found in plants and their antimicrobial and antioxidant activities is well demonstrated. One of its beneficial biological effects is the neuroprotective activity, showing preclinical activities on Alzheimer, Parkinson, and Huntington diseases, and even in amyotrophic lateral sclerosis. Also, myricetin has revealed other biological activities, among them as antidiabetic, anticancer, immunomodulatory, cardiovascular, analgesic and antihypertensive. However, few clinical trials have been performed using myricetin as nutraceutical. Thus, this review provides new insights on myricetin preclinical pharmacological activities, and role in selected clinical trials. BioMed Central 2020-08-01 /pmc/articles/PMC7395214/ /pubmed/32738903 http://dx.doi.org/10.1186/s12906-020-03033-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Taheri, Yasaman
Suleria, Hafiz Ansar Rasul
Martins, Natália
Sytar, Oksana
Beyatli, Ahmet
Yeskaliyeva, Balakyz
Seitimova, Gulnaz
Salehi, Bahare
Semwal, Prabhakar
Painuli, Sakshi
Kumar, Anuj
Azzini, Elena
Martorell, Miquel
Setzer, William N.
Maroyi, Alfred
Sharifi-Rad, Javad
Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications
title Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications
title_full Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications
title_fullStr Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications
title_full_unstemmed Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications
title_short Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications
title_sort myricetin bioactive effects: moving from preclinical evidence to potential clinical applications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395214/
https://www.ncbi.nlm.nih.gov/pubmed/32738903
http://dx.doi.org/10.1186/s12906-020-03033-z
work_keys_str_mv AT taheriyasaman myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications
AT suleriahafizansarrasul myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications
AT martinsnatalia myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications
AT sytaroksana myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications
AT beyatliahmet myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications
AT yeskaliyevabalakyz myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications
AT seitimovagulnaz myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications
AT salehibahare myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications
AT semwalprabhakar myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications
AT painulisakshi myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications
AT kumaranuj myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications
AT azzinielena myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications
AT martorellmiquel myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications
AT setzerwilliamn myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications
AT maroyialfred myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications
AT sharifiradjavad myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications